Clinical trial
Study of EC0225 for the Treatment of Refractory or Metastatic Tumors
NCT00441870 · Endocyte, Industry · Completed
Key facts
| NCT number | NCT00441870 |
|---|---|
| Title | Study of EC0225 for the Treatment of Refractory or Metastatic Tumors |
| Official title | Protocol EC-0225-01: A Phase 1 Study of EC0225 Administered Weeks 1 and 3 of a 4-Week Cycle |
| Lead sponsor | Endocyte, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate), 99mTC-EC20 (Folic acid-technetium 99m conjugate) |
| Enrollment | 77 |
| Start date | Feb 1, 2007 |
| Primary completion | Nov 1, 2010 |
| Completion | Nov 1, 2010 |
| First posted | Mar 1, 2007 |
| Last update posted | Mar 9, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: